{'fraction_non_alphanumeric': 0.02126044039483675, 'fraction_numerical': 0.0015186028853454822, 'mean_word_length': 5.336538461538462, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Isoprenaline-induced changes in type I inhibitor activity as an index of beta-adrenergic receptor subsensitivity.

Isoprenaline produced a dose-dependent decrease in the activity of an endogenous, specific inhibitor of cAMP-dependent protein kinase (type I inhibitor) in rat hippocampus, brain stem and pineal gland. Prolonged, 21-days treatment with some antidepressant (imipramine, nomifensin and mianserin) markedly reduced the response of the type I inhibitor activity to isoprenaline. To obtain the significant decrease of the type I inhibitor activity, five times higher dose of isoprenaline had to be used in these animals than in control rats. Mianserin is known to produce a decrease of the activity of adenylate cyclase coupled to beta-adrenergic receptors without changing the number of receptor binding sites. In the present study we have shown that also mianserin after prolonged treatment produces subsensitivity of beta-adrenergic receptors when measured by the response of the type I inhibitor activity to isoprenaline. Single doses of imipramine, nomifensin and mianserin did not change the isoprenaline-induced decrease of the type I inhibitor activity. It seems that the isoprenaline-induced decreased of the type I inhibitor activity can be used as an index of beta-adrenergic receptor reactivity.